Minchella Peter A, Armitage Andrew E, Darboe Bakary, Jallow Momodou W, Drakesmith Hal, Jaye Assan, Prentice Andrew M, McDermid Joann M
Department of Nutritional Sciences, Cornell University, Ithaca, NY;
Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom;
J Nutr. 2015 Jun;145(6):1194-201. doi: 10.3945/jn.114.203158. Epub 2015 Apr 22.
Early and chronic inflammation is a hallmark of HIV infection, and inflammation is known to increase hepcidin expression. Consequently, hepcidin may be a key determinant of the iron homeostasis and anemia associated with poorer HIV prognoses.
The objective of this study was to understand how hepcidin is related to anemia, iron homeostasis, and inflammation at HIV diagnosis and to investigate associations between hepcidin and all-cause mortality in HIV infection.
In a retrospective cohort, baseline plasma hepcidin was measured by competitive enzyme immunoassay within 3 mo of HIV diagnosis in 196 antiretroviral-naive Gambians. Iron homeostasis [hemoglobin, plasma transferrin, ferritin, iron, soluble transferrin receptor (sTfR)] and inflammation [α1-antichymotrypsin (ACT)] from the same plasma sample were available, as were absolute CD4 cell counts, age, gender, body mass index (BMI), and HIV type.
Anemia was common across the spectrum of immunosuppression [CD4 cell counts (prevalence of anemia): >500 cells/μL (68%), 200-500 cells/μL (73%), and <200 cells/μL (89%); P = 0.032] and in men (81%) and women (76%). Increasing hepcidin was associated with iron homeostasis biomarkers (higher ferritin and lower transferrin, hemoglobin, and sTfR), inflammation (higher ACT), and key health indicators (lower CD4 or BMI, advancing age, and male gender; P < 0.001 except for hemoglobin, P = 0.021). Elevated hepcidin was associated with greater all-cause mortality in a dose-dependent manner [intermediate vs. lowest tertile: unadjusted HR (95% CI), 1.95 (1.22, 3.10); upper vs. lowest tertile: 3.02 (1.91, 4.78)]. Principal components analysis identified 2 patterns composed of hepcidin-ferritin-transferrin, with or without ACT, and iron-sTfR-hemoglobin that may distinguish inflammation and erythropoiesis iron functions.
Elevated hepcidin is independently associated with greater mortality in men and women with HIV infection, and hepcidin is also part of a complex relation linking iron homeostasis, anemia, and HIV. Understanding the mechanisms and role of hepcidin modulation may further guide evidence-based interventions needed to counter detrimental iron homeostasis and anemia in HIV infection.
早期和慢性炎症是HIV感染的一个标志,并且已知炎症会增加铁调素的表达。因此,铁调素可能是与HIV预后较差相关的铁稳态和贫血的关键决定因素。
本研究的目的是了解在HIV诊断时铁调素如何与贫血、铁稳态和炎症相关,并调查铁调素与HIV感染中全因死亡率之间的关联。
在一项回顾性队列研究中,对196名未接受过抗逆转录病毒治疗的冈比亚人在HIV诊断后3个月内通过竞争性酶免疫测定法测量基线血浆铁调素。同一血浆样本中的铁稳态指标(血红蛋白、血浆转铁蛋白、铁蛋白、铁、可溶性转铁蛋白受体[sTfR])和炎症指标(α1-抗糜蛋白酶[ACT])均可获得,同时还有绝对CD4细胞计数、年龄、性别、体重指数(BMI)和HIV类型。
贫血在整个免疫抑制范围内都很常见[CD4细胞计数(贫血患病率):>500个细胞/μL(68%)、200 - 500个细胞/μL(73%)和<200个细胞/μL(89%);P = 0.032],在男性(81%)和女性(76%)中也很常见。铁调素升高与铁稳态生物标志物(较高的铁蛋白和较低的转铁蛋白、血红蛋白和sTfR)、炎症(较高的ACT)以及关键健康指标(较低的CD4或BMI、年龄增长和男性性别;除血红蛋白外P < 0.001,血红蛋白P = 0.021)相关。铁调素升高与全因死亡率增加呈剂量依赖性相关[中间三分位数与最低三分位数:未调整的HR(95%CI),1.95(1.22,3.10);最高三分位数与最低三分位数:3.02(1.91,4.78)]。主成分分析确定了由铁调素-铁蛋白-转铁蛋白组成的两种模式,有或没有ACT,以及铁-sTfR-血红蛋白模式,这些模式可能区分炎症和红细胞生成中铁的功能。
铁调素升高与HIV感染的男性和女性较高的死亡率独立相关,并且铁调素也是连接铁稳态、贫血和HIV的复杂关系的一部分。了解铁调素调节的机制和作用可能会进一步指导在HIV感染中对抗有害铁稳态和贫血所需的循证干预措施。